Evidence map›Paper›PMID 31221217›Full record

ArticleSystematic reviews2019

Antibiotic treatment for ocular toxoplasmosis: a systematic review and meta-analysis: study protocol.

John E Feliciano-Alfonso, Andrés Vargas-Villanueva, María Alejandra Marín, Laura Triviño, Natalia Carvajal, Manuela Moreno, Tatiana Luna, Clara Lopez de Mesa, Juliana Muñoz-Ortiz, Alejandra de-la-Torre

Open access · goldAbstract read
In one paragraph

Article in Systematic reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

John E Feliciano-AlfonsoDepartamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia.
Andrés Vargas-VillanuevaEscuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
María Alejandra MarínEscuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Laura TriviñoEscuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Natalia CarvajalEscuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Manuela MorenoEscuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Tatiana LunaEscuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Bogotá, Colombia.
Clara Lopez de MesaEscuela Superior de Oftalmología-Instituto Barraquer de América, Bogotá, Colombia.
Juliana Muñoz-OrtizEscuela Superior de Oftalmología-Instituto Barraquer de América, Bogotá, Colombia.
Alejandra de-la-TorreNeURos research group, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia. alejadelatorre@yahoo.com.
Universidad del Rosario · COInstituto Barraquer de América · COUniversidad Nacional de Colombia · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOcular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence, and the severity and duration of acute symptoms. Although OT is a very common cause of infectious posterior uveitis, its treatment remains controversial. Through our systematic review and meta-analysis, we aim to provide the best possible evidence-based information on the safety and effectiveness of the different antibiotic regimes for OT.

methodsThis systematic review protocol has been developed based on PRISMA-P guidelines for reporting systematic reviews evaluating health care interventions. We will include all published and unpublished randomized controlled trials (RCTs) comparing different antibiotics used for the treatment of OT. We will consider changes in visual acuity, number of recurrences, improvement or worsening of ocular inflammation, size of lesion, and adverse effects as our outcomes. Screening, data extraction, and quality assessment will be undertaken by two reviewers with disagreements resolved through discussion. Studies that compared antibiotics with placebo will be excluded. The reviews will be assessed for quality and relevance. We will assess the risk of bias in five domains according to Cochrane group's tool. The type of data will dictate measures of treatment effect. We will use a random-effects model to calculate our meta-analysis, as eligible studies represent clinically varied populations of participants. DISCUSSION: The strength of our study will lie in the exhaustive and systematic nature of the literature search, as well as in its methods for assessing quality and analyzing RCT data. Considering the controversial efficacy of the treatment for OT, our study will contribute to improving the existing evidence on the effectiveness of different antibiotics. Future studies may be conducted to increase physicians' awareness of antibiotic therapies, improving the health of patients with OT. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018085468.

Indexed as

Anti-Bacterial AgentsAntiprotozoal AgentsToxoplasmosis, OcularHumansMeta-Analysis as TopicSystematic Reviews as TopicToxoplasmaTreatment OutcomeAnti-Bacterial AgentsAntiprotozoal AgentsAnti-bacterial agentsToxoplasmaToxoplasmosis, ocularUveitis

Identifiers

PMID31221217
PMCPMC6587239
OpenAlexW2949982112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.